Arteriocyte, Inc.  (CSCRM startup company) is an early-stage company developing proprietary stem cell based therapies to grow new blood vessels for patients with a variety of vascular diseases.

Athersys, Inc.  is a Founding member of CSCRM and is actively developing therapeutics based on the Multipotent Adult Progenitor Cell (MAPC) technology, originally developed by Dr. Catherine Verfaillie and colleagues at the University of Minnesota and licensed exclusively to Athersys. The company has numerous collaborations with CSCRM investigators and institutions to rapidly advance its product candidates to the clinic.

Cell Targeting, Inc.  (CSCRM startup company) addresses the fundamental problems of cellular therapy: the quantity and location of stem cells.

Cleveland Clinic  is one of the world's largest and busiest health centers and is a Founding member of CSCRM. Patients come to The Cleveland Clinic from all over the world for advanced treatment in all illnesses and disorders of the body. In cardiology and cardiac surgery, they lead the nation as evidenced by the Heart Center’s number one rank in America for eleven years in row in U.S. News.

RegenRx  (CSCRM startup company) capitalizes on the induction of homing in stem cells to areas of myocardial injury by specific factors.